Billion Dollar Blueprint: The Journey to Blockbuster Status
What’s the secret formula for creating the next pharmaceutical behemoth? In this eBook discover whether indication expansion drives revenue growth, the pros and cons of in-house vs. outsourced development, and more.
Evaluate World Preview 2024: Pharma's Growth Boost
Last year’s Age of Uncertainty has given way to more predictable realities, including the dominance of obesity and other big diseases, a wider range of modalities and an IRA that’s here to stay. Check out all the data and analysis in the new report.
Licence Drivers: Trends in Pharma Dealmaking
Licensing deals are a critical part of the symbiotic relationship between Big Pharma and biotechs. Big players, many of whom are facing down huge losses through patent expiry, have to balance risk aversion with the need to strengthen pipelines. Meanwhile, biotech and smaller pharma companies must secure investment to get their assets to the next stage.
Obesity: The Next Questions
Before the incretin drug class proved its potential, the notion that obesity could be treated with a pill or injection was almost science fiction. Now, it’s very much fact and the big question is; how large could this market become?
AI and ML in Pharma: Redefining the Forecasting Landscape
Join leading experts from J+D Forecasting as they shed light on the transformative potential of AI and ML in pharmaceutical forecasting, enabling more precise predictions, improved decision-making, and strategic guidance for the industry.
Evaluate radically transforms your confidence in strategic portfolio decisions.
In biopharma, making the right decisions has an incredible impact on patients’ lives. Making those decisions requires a deep understanding of your market; from identifying opportunities and mitigating risk to evaluating assets and pipelines.
Evaluate provides a complete and dynamic view of the pharmaceutical market, with innovative solutions that bring together technology, real world data, and deep expertise to help you make portfolio decisions that drive growth.
HOW WE HELP
Connected data gives you a clearer picture.
Evaluate gives you the understanding and time you need to drive better decisions.
Market Opportunity Sizing
Identify the market that offers the greatest potential for your business so you can confidently prioritise assets and allocate resources.
Commercial Opportunity Assessment
Develop a robust view of potential partners and licensing opportunities to boost your pipeline and amplify your commercial success.
Competitive Landscape Analysis
Build a clear analysis of the evolving landscape – market dynamics, emerging trends and key players – and make strategic moves that strengthen your position.
Company Profiling
Monitor key companies so you can track potential partners and competitors and find opportunities in a constantly changing environment.
Asset Screening
Obtain a clear and unbiased assessment of asset value to drive licensing decisions and ensure you invest in assets with the highest potential for success.
Deal Benchmarking
Bring confidence to your allocation strategy with timely external benchmarking data across the R&D landscape.
We collect,
collaborate and connect.
OUR SOLUTIONS
Insight at Your Fingertips
Access our world-class forecasting, analysis and machine learning-driven insight to help you reduce risk, maximise returns, and make smarter decisions about your portfolio strategy.
MARKET REPORTS
Trends & Analysis
Dive into our market reports covering sector performance and valuation, emerging trends and global forecasts. Stay ahead of the competition with the latest developments that impact your portfolio strategy.
OUR SERVICES
Consulting & Analytics
Tap into our expertise and reach your goals with our collaborative team of specialists, providing technology-enabled consulting, strategic commercial insights, and recommendations across the product lifecycle.
Latest Solutions & Insights
Understand the context. Data-driven insights and analysis for the pharma, biotech and medtech sectors.
If there’s one thing that the experts at Evaluate love, it’s rummaging around in data to identify trends in the pharma market. One area that is always fascinating to explore ...
September 27, 2024
Volume is up but value is down. That’s the headline of the dealmaking scene for the first half of 2024. There’s not been a mega-merger in the vein of 2023’s ...
August 8, 2024
Kelly Chamberlain may not have been at the company very long, but that didn’t stop me swooping in to find out a little more about her. Kelly has joined Norstella, ...
If you missed our recent webinar, AI and ML in Pharma: Redefining the Forecasting Landscape, then I hope it’s because you were on a lovely vacation somewhere. Now that you’re ...
July 24, 2024
There is no shortage of discussion about the opportunities presented by artificial intelligence and AI in the pharma industry. 50% of global healthcare companies plan to implement AI strategies by ...
Evaluate’s annual World Preview report is a must-read for many in the pharma industry. Each year, we pull together some of our key pharma forecasts to build a picture of ...